sorafenib has been researched along with Innate Inflammatory Response in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, K; Li, Y; Lu, X; Ren, X | 1 |
| Cho, M; Hong, YM; Yoon, KT | 1 |
| Hoe, HS; Kim, J; Park, JH; Park, SK | 1 |
| Augustyns, K; Bräsen, JH; Feldmann, F; Fulda, S; Goossens, V; Hofmans, S; Jeong, M; Joossens, J; Lee, EW; Linkermann, A; Martens, S; Song, J; Takahashi, N; Tonnus, W; Van der Veken, P; Vandenabeele, P | 1 |
| Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF | 1 |
| Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á | 1 |
| Kang, R; Liu, J; Tang, D; Wen, Q; Zhou, B | 1 |
| Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T | 1 |
| Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W | 1 |
| Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M | 1 |
| Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P | 1 |
| Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM | 1 |
| Allavena, P; Mantovani, A | 1 |
| Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K | 1 |
| Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC | 1 |
| Brocheriou, I; Deray, G; Izzedine, H; Rixe, O | 1 |
2 review(s) available for sorafenib and Innate Inflammatory Response
| Article | Year |
|---|---|
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
1 trial(s) available for sorafenib and Innate Inflammatory Response
| Article | Year |
|---|---|
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
13 other study(ies) available for sorafenib and Innate Inflammatory Response
| Article | Year |
|---|---|
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Progression-Free Survival; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice.
Topics: Alzheimer Disease; Animals; Astrocytes; Cyclooxygenase 2; Disease Models, Animal; Inflammation; Interleukin-1beta; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2021 |
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; Reperfusion Injury; Sorafenib; Tumor Necrosis Factor-alpha | 2017 |
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2017 |
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Inflammation; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Severity of Illness Index; Sorafenib; Treatment Outcome | 2018 |
The release and activity of HMGB1 in ferroptosis.
Topics: Animals; Autophagy; Carbolines; Cell Death; Cell Line, Tumor; Chloroquine; Ferritins; Fibroblasts; HMGB1 Protein; Humans; Immunity, Innate; Inflammation; Iron Overload; Lipid Peroxidation; Macrolides; Mice; Neoplasms; Oximes; Piperazines; Sorafenib; Sulfonamides; Toll-Like Receptor 4 | 2019 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2016 |
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib | 2016 |
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Inflammation; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Analysis | 2017 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Severity of Illness Index; Sorafenib | 2012 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous | 2012 |
Interstitial nephritis in a patient taking sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Inflammation; Kidney; Kidney Neoplasms; Leukocytes; Male; Nephritis, Interstitial; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |